Improvement of HepG2/C3a cell functions in a microfluidic biochip

Biotechnology and Bioengineering

Volumn 108, Issue 7, 2011, Pages 1704-1715

  Prot, Jean Matthieu ^a   Aninat, Caroline ^b   Griscom, Laurent ^c   Razan, Florence ^c   Brochot, Céline ^d   Guillouzo, Christiane Guguen ^b   Legallais, Cécile ^a   Corlu, Anne ^b   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c CY Cergy Paris Université   (France)

^d INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Hepatocytes; Liver; Microfluidic biochip; PDMS; Transcriptomic

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; CELL CULTURE; CELL DEATH; ENZYMES; GENES; LIVER; METABOLISM; MICROCHANNELS; MICROFLUIDICS; PHYSIOLOGY; PULSE WIDTH MODULATION; TISSUE ENGINEERING;

AFFYMETRIX GENECHIP; CELL ORGANIZATION; CYTOCHROMES P450; HEPATIC METABOLISMS; HEPATOCYTES; MICRO FLUIDIC BIOCHIPS; POLYDIMETHYLSILOXANE PDMS; TRANSCRIPTOMIC;

BIOCHIPS;

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DIMETICONE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOCHIP; CELL CULTURE; CELL GROWTH; CELL STRAIN HEPG2; CYTOTOXICITY; GLUCOSE INTAKE; HUMAN; HUMAN CELL; LIVER METABOLISM; MICROFLUIDICS; TRANSCRIPTOMICS; XENOBIOTIC METABOLISM;

EID: 79953236870     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23104     Document Type: Article

References (44)

1. Akiyama TE, Gonzalez FJ. 2003. Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim Biophys Acta 1619: 223-234.
2. Asha S, Vidyavathi M. 2010. Role of human liver microsomes in in vitro metabolism of drugs: A review. Appl Biochem Biotechnol 160: 1699-1722.
3. Baudoin R, Corlu A, Griscom L, Legallais C, Leclerc E. 2007a. Trends in the development of microfluidic cell biochips for in vitro hepatotoxicity. Toxicol In Vitro 21: 535-544.
4. Baudoin R, Griscom L, Monge M, Legallais C, Leclerc E. 2007b. Development of a renal microchip for in vitro distal tubule models. Biotechnol Prog 23: 1245-1253.
5. Baudoin R, Griscom L, Prot JM, Legallais C, Leclerc E. 2011. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor. Biochem Eng J 53: 172-181.
6. Borenstein JT, Terai H, King K, Weinberg C, Kaazempur-Mofrad M, Vacanti JP. 2002. Microfabrication technology for vascularized tissue engineering. Biomed Microdevices 4: 167-175.
7. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
8. Chang T, Hughes-Fulford M. 2009. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A 15: 559-567.
9. Chao P, Maguire T, Novik E, Cheng KC, Yarmush ML. 2009. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol 78: 625-632.
10. Charati S, Stern S. 1998. Diffusion of gases in silicone polymer: Molecular dynamics simulations. Macromolecules 31: 5529-5535.
11. De Bartolo L, Bader A. 2001. Review of a flat membrane bioreactor as a bioartificial liver. Ann Transplant 6: 40-46.
12. De Kanter R, Monshouwer M, Meijer D, Groothuis G. 2002. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Curr Drug Metab 3: 39-59.
13. Domansky K, Inman W, Serdy J, Dash A, Lim MH, Griffith LG. 2010. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 10: 51-58.
14. Franklin MR, Yost GS. 2000. Biotransformation: A balance between bioactivation and detoxification. In: Williams PL, James RC, Roberts SM, editors. Principles of toxicology: Environmental and industrial applications. New York, NY: John Wiley & Sons, pp. 57-86.
15. Gebhardt R, Hengstler JG, Muller D, Glockner R, Buenning P, Laube B, Schmelzer E, Ullrich M, Utesch D, Hewitt N, Ringel M, Hilz BR, Bader A, Langsch A, Koose T, Burger HJ, Maas J, Oesch F. 2003. New hepatocyte in vitro systems for drug metabolism: Metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35: 145-213.
16. Griffith L, Naughton G. 2002. Tissue enginnering-Current challenges and expanding opportunities. Science 295: 1009-1014.
17. Guillouzo A. 1998. Liver cell models in in vitro toxicology. Environ Health Respect 106: 511-532.
18. Guillouzo A. 2008. New perspectives in the use of human hepatocytes in the preclinical drug development process. Ann Pharm Fr 66: 288-295.
19. Horiuchi SI, Ishida S, Hongo T, Ishikawa Y, Miyajima A, Sawada J, Ohno Y, Nakazawa K, Ozawa S. 2009. Global gene expression changes including drug metabolism and disposition induced by three-dimensional culture of HepG2 cells-Involvement of microtubules. Biochem Biophys Res Commun 378: 558-562.
20. Kelly J, Sussman N. 2000. A fluorescent cell-based assay for cytochrome P-450 isozyme 1A2 induction and inhibition. J Biomol Screen 5: 249-254.
21. Keselowsky BG, Collard DM, Garcia AJ, 2003. Surface chemistry modulates fibronectin conformation and directs integrin binding and specificity to control cell adhesion. J Biomed Mater Res A 66: 247-259.
22. Knowles BB, Howe CC, Aden DP. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499.
23. Leclerc E, Sakai Y, Fujii T. 2003. Cell culture in 3-dimensional microfluidic structure of PDMS (polydimethylsiloxane). Biomed Microdevices 5: 109-114.
24. Leclerc E, Sakai Y, Fujii T. 2004. Perfusion culture of fetal human hepatocytes in microfluidic-environments. Biochem Eng J 20: 143-148.
25. Lee JN, Park C, Whitesides GM. 2003. Solvent compatibility of poly(dimethylsiloxane)-based microfluidic devices. Anal Chem 75: 6544-6554.
26. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. 2010. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochemical Pharmacology 79: 1036-1044.
27. Oda H, Yoshida Y, Kawamura A, Kakinuma A. 2008. Cell shape, cell-cell contact, cell-extracellular matrix contact and cell polarity are all required for the maximum induction of CYP2B1 and CYP2B2 gene expression by phenobarbital in adult rat cultured hepatocytes. Biochem Pharmacol 75: 1209-1217.
28. Park J, Berthiaume F, Toner M, Yarmush ML, Tilles AW. 2005. Microfabricated grooved substrates as platforms for bioartificial liver reactors. Biotechnol Bioeng 90: 632-644.
29. Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL. 2010. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: Human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet 25: 16-27.
30. Parmar D, Dhawan A, Seth PK. 1998. Evidence for O-dealkylation of 7-pentoxyresorufin by cytochrome P450 2B1/2B2 isoenzymes in brain. Mol Cell Biochem 189: 201-205.
31. Powers MJ, Domansky K, Udapadhia A, Kazempur-Mofrad MR, Kursawky P, Janigan D, Wack KE, Stolz DB, Kamm R, Griffith L. 2001. A microarray perfusion bioreactor for 3D liver culture. Biotechnol Bioeng 78: 257-268.
32. Powers MJ, Janigian DM, Wack KE, Baker CS, Stolz DB, Griffith LG. 2002. Functional Behavior of Primary Rat Liver Cells in a Three-Dimensional Perfused Microarray Bioreactor. Tissue Eng 8: 499-513.
33. Richert L, Binda D, Hamilton G, Viollon-Abadie C, Alexandre E, Bigot-Lasserre D, Bars R, Coassolo P, LeCluyse E. 2002. Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol In Vitro 16: 89-99.
34. Schmierer B, Hill CS. 2007. TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8: 970-982.
35. Schrem H, Klempnauer J, Borlak J. 2002. Liver-enriched transcription factors in liver function and development. Part I: The hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev 54: 129-158.
36. Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, Samson LD, Tannenbaum SR, Griffith LG. 2005. A microscale in vitro physiological model of the liver: Predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 6: 569-592.
37. Sung JH, Kam C, Shuler MJ. 2010. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10: 446-455.
38. Toh YC, Lim TC, Tai D, Xiao G, van Noort D, Yu H. 2009. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 9: 2026-2031.
39. Viravaidya K, Shuler ML. 2004. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog 20: 590-597.
40. Vrzal R, Daujat-Chavanieu M, Pascussi JM, Ulrichova J, Maurel P, Dvorak Z. 2008. Microtubules-interfering agents restrict aryl hydrocarbon receptor-mediated CYP1A2 induction in primary cultures of human hepatocytes via c-jun-N-terminal kinase and glucocorticoid receptor. Eur J Pharmacol 581: 244-254.
41. Yamasaki C, Tateno C, Aratani A, Ohnishi C, Katayama S, Kohashi T, Hino H, Marusawa H, Asahara T, Yoshizato K. 2006. Growth and differentiation of colony-forming human hepatocytes in vitro. J Hepatol 44: 749-757.
42. Zaret KS. 1996. Molecular genetics of early liver development. Annu Rev Physiol 58: 231-251.
43. Zhang M, Lee P, Hung P, Johnson T, Lee L, Kazempur-Mofrad MR. 2008. Microfluidic environment for high density hepatocyte culture. Biomed Microdevices 10: 117-121.
44. Zimmerman HJ. 1998. Acetaminophen hepatotoxicity. Clin Liver Dis 2: 523-541.